Results for this period
Third quarter1 January 2026–30 September 2026ConsolidatedIFRSThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ thousand).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Revenue from the drug discovery and development business increased by ¥1,657.357 million year on year, while revenue from the radiopharmaceuticals business increased by ¥305.612 million. The drug discovery and development business reported a segment loss of ¥3,154.943 million, while the radiopharmaceuticals business reported segment profit of ¥355.158 million. The company expects to record upfront contract payments and research and development milestone income, among other items, in the second half.
A description of material events, etc. is included. Although the company continues to record operating losses, it has determined that there is no material uncertainty regarding the going concern assumption, due to the refinancing of its syndicated loan agreement and sufficient cash liquidity.
| Item | Details |
|---|---|
| Fiscal Period Classification | Third quarter |
| Accounting standards | IFRS |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 January 2026–30 September 2026 |
| Net Sales | ¥14,820 million (YoY +15.3%) |
| Operating profit | ¥-2,867 million |
| Ordinary income | ¥-3,153 million |
| Profit attributable to owners of the parent | ¥-2,362 million |
| Net income per share | -¥18.35 |
| Equity ratio | End of the current fiscal period 67.7 / End of previous period 66.9 |
| Total assets | ¥71,151 million |
| Net assets | ¥48,203 million |
| Cash flows from operating activities | ¥-3,669,528 thousand |
| Cash flows from investing activities | ¥-1,209,401 thousand |
| Cash flows from financing activities | ¥-3,525,406 thousand |
| Cash and cash equivalents at end of period | ¥20,284,785 thousand |
| Full-year earnings forecast | Net Sales ¥32,000 million (YoY +72.8%) / Operating profit ¥4,600 million / Ordinary income ¥4,300 million / Net income ¥3,000 million |
| Annual Dividend Forecast | ¥0 → ¥0（0.0%） |
| Segment revenue | Drug discovery and development business ¥2,787,969 thousand, Radiopharmaceutical Business ¥12,032,382 thousand |
| Segment profit | Drug discovery and development business ¥-3,154,943 thousand, Radiopharmaceutical Business ¥355,158 thousand |
| Depreciation and amortization | ¥1,465,599 thousand |
| Impairment loss | ¥0 thousand |
| Disclosure regarding the going concern assumption | A description of material events, etc. is included. Although the company continues to record operating losses, it has determined that there is no material uncertainty regarding the going concern assumption, due to the refinancing of its syndicated loan agreement and sufficient cash liquidity. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement Not disclosed |
| Changes in the scope of consolidation | No (0 additions, 0 exclusions) |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | None (対象者：Not disclosed) |
| Issued Shares at Period-End | 130,010,400 |
| Treasury Shares at Period-End | 1,442,676 |
| Factors Behind Changes in Business Performance | Revenue from the drug discovery and development business increased by ¥1,657.357 million year on year, while revenue from the radiopharmaceuticals business increased by ¥305.612 million. The drug discovery and development business reported a segment loss of ¥3,154.943 million, while the radiopharmaceuticals business reported segment profit of ¥355.158 million. The company expects to record upfront contract payments and research and development milestone income, among other items, in the second half. |
Items this document does not state (8)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue from the drug discovery and development business increased by ¥1,657.357 million year on year, while revenue from the radiopharmaceuticals business also increased by ¥305.612 million. The company expects to record upfront contract payments and research and development milestone income, among other items, in the second half, and expects to report an operating profit for the full year.